Sydney-based EMVision has announced a US$10 million strategic investment from Keysight Technologies, for clinical trials, production capacity, and commercialization of its emu\u2122 brain scanner, a breakthrough advancement in stroke care designed to provide rapid diagnostic imaging to accelerate the delivery of urgent, life-saving care, particularly in settings where traditional imaging modalities such as CT and MRI are not readily available.<\/p>\n\n\n\n
The emu\u2122 device is operated at the point of care, with a simple cap placed on the patient’s head for quick scans and image generation. It combines safe, ultra-high frequency radio signals with powerful Artificial Intelligence to produce rapid insights directly at the patient\u2019s bedside.<\/p>\n\n\n\n
emu\u2122 can be operated by any healthcare professional with minimal training. Targeted for use in intensive care units, stroke and neurology wards, and rural emergency departments, emu\u2122 has the potential to improve survival rates and quality of life after stroke and other neurological events requiring urgent intervention.<\/p>\n\n\n\n
The emu\u2122\ufe0f device is neither available for sale nor evaluated by the FDA or other global regulators. The devices may only be used by authorized sites in controlled clinical investigations.<\/em><\/p>","protected":false},"excerpt":{"rendered":" Sydney-based EMVision has announced a US$10 million strategic investment from Keysight Technologies, for clinical trials, production capacity, and commercialization of its emu\u2122 brain scanner, a breakthrough advancement in<\/p>","protected":false},"author":2,"featured_media":29168,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[5,10],"tags":[699,594],"class_list":["post-29167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-asia-pacific","category-strategic-development","tag-australia","tag-financing"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/posts\/29167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/comments?post=29167"}],"version-history":[{"count":3,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/posts\/29167\/revisions"}],"predecessor-version":[{"id":29172,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/posts\/29167\/revisions\/29172"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/media\/29168"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/media?parent=29167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/categories?post=29167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/de\/wp-json\/wp\/v2\/tags?post=29167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}